欧美va天堂在线观看,国产一级精品毛片基地

首頁(yè)> 產(chǎn)品列表> 電子材料化學(xué)氣相沉積與原子層沉積前體材料>

VCP746

NMR下載 COA and HPLC MSDS下載
names：
5-amino-4-benzoyl-N-(6-((9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-9H-purin-6-yl)amino)hexyl)-3-(3-(trifluoromethyl)phenyl)thiophene-2-carboxamide
CAS號(hào)：
1582751-84-5
MDL Number：
MF(分子式)： C35H36F3N7O6S MW(分子量)： 739.7712
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車立即購(gòu)買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫(xiě)您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	5-amino-4-benzoyl-N-(6-((9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-9H-purin-6-yl)amino)hexyl)-3-(3-(trifluoromethyl)phenyl)thiophene-2-carboxamide
英文別名	VCP-746; VCP 746; VCP746;
CAS號(hào)	1582751-84-5
Inchi	InChI=1S/C35H36F3N7O6S/c36-35(37,38)21-12-8-11-20(15-21)23-24(26(47)19-9-4-3-5-10-19)30(39)52-29(23)33(50)41-14-7-2-1-6-13-40-31-25-32(43-17-42-31)45(18-44-25)34-28(49)27(48)22(16-46)51-34/h3-5,8-12,15,17-18,22,27-28,34,46,48-49H,1-2,6-7,13-14,16,39H2,(H,41,50)(H,40,42,43)/t22-,27-,28-,34-/m1/s1
InchiKey	BXNCSGUIWDCTBJ-QQLQPOFESA-N
分子式 Formula	C35H36F3N7O6S
分子量 Molecular Weight	739.7712
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說(shuō)明	VCP746(CAS:1582751-84-5):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過(guò)程療，該產(chǎn)品非藥用，非食用。
Introduction	VCP-746 is a potent adenosine A2B receptor agonist that stimulates anti-fibrotic signalling. VCP746 reduces hypertrophy in a rat neonatal cardiac myocyte model. VCP746 is a hybrid molecule consisting of an adenosine moiety linked to an adenosine A1 receptor (A1AR) allosteric modulator moiety. At the A1AR, VCP746 mediated cardioprotection in the absence of haemodynamic side effects such as bradycardia.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Vecchio EA, Chuo CH, Baltos JA, Ford L, Scammells PJ, Wang BH, ChristopoulosA, White PJ, May LT. The hybrid molecule, VCP746, is a potent adenosine A2Breceptor agonist that stimulates anti-fibrotic signalling. Biochem Pharmacol.2016 Oct 1;117:46-56. doi: 10.1016/j.bcp.2016.08.007. Epub 2016 Aug 9. PubMedPMID: 27520486.

[2]Chuo CH, Devine SM, Scammells PJ, Krum H, Christopoulos A, May LT, White PJ,Wang BH. VCP746, a novel A1 adenosine receptor biased agonist, reduceshypertrophy in a rat neonatal cardiac myocyte model. Clin Exp Pharmacol Physiol.2016 Oct;43(10):976-82. doi: 10.1111/1440-1681.12616. PubMed PMID: 27377874.

[3] Baltos JA, Gregory KJ, White PJ, Sexton PM, Christopoulos A, May LT.Quantification of adenosine A(1) receptor biased agonism: Implications for drugdiscovery. Biochem Pharmacol. 2016 Jan 1;99:101-12. doi:10.1016/j.bcp.2015.11.013. Epub 2015 Nov 12. PubMed PMID: 26581123.

[4] Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA, Sexton PM,Scammells PJ, Christopoulos A. Separation of on-target efficacy from adverseeffects through rational design of a bitopic adenosine receptor agonist. ProcNatl Acad Sci U S A. 2014 Mar 25;111(12):4614-9. doi: 10.1073/pnas.1320962111.Epub 2014 Mar 11. PubMed PMID: 24619092; PubMed Central PMCID: PMC3970544.

對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開(kāi)

SDS 1.0 英文

展開(kāi)